Amryt Pharma plc logo
Amryt Pharma plc AMYT

Annual report 2021
added 12-23-2023

report update icon

Amryt Pharma plc Balance Sheet 2011-2026 | AMYT

Annual Balance Sheet Amryt Pharma plc

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- 70.6 M 112 M 7.78 M -11.2 M -8.7 M -16.8 M -17.4 M -31.5 M -239 K -1.61 K

Long Term Debt

- 188 M 178 M 19 M 12.7 M - - - - - -

Long Term Debt Current

1.54 M 963 K 571 K - - - - - - - -

Total Non Current Liabilities

- 369 M - 72.5 M 58.1 M 30.2 M - 79 K 169 K - -

Total Liabilities

459 M 470 M 395 M 84.5 M 69.8 M 33.9 M 504 K 13.2 M 842 K 439 K 43.4 K

Deferred Revenue

- - 23 M - - - - - - - -

Retained Earnings

- -236 M 84 M -69.6 M -42.1 M -9.46 M -44.8 M -5.05 M -2.49 M -3.11 M -3.72 M

Total Assets

816 M 537 M 527 M 80.8 M 96.1 M 68.7 M 17 M 69.2 M 43.7 M 698 K 1.13 M

Cash and Cash Equivalents

113 M 119 M 67.2 M 11.2 M - - - - - - -

Book Value

357 M 66.1 M 132 M -3.7 M 26.3 M 34.7 M 16.5 M 55.9 M 42.8 M 259 K 1.09 M

Total Shareholders Equity

- 66.1 M 132 M -3.7 M - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Amryt Pharma plc

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - 4.05 M - - - 4.57 M - - - 1.05 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - 302 M - - - 369 M - - - 293 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - - - 459 M - - - 470 M - - - 395 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - - -233 M - - - -236 M - - - -131 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - - - 816 M - - - 537 M - - - 527 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - - 113 M - - - 119 M - - - 67.2 M - - - 11.2 M - - - 24.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

- - - - 357 M - - - 66.1 M - - - 132 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - - 357 M - - - 66.1 M - - - 132 M - - - -3.7 M - - - 26 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Amryt Pharma plc, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 5.15 15.21 % $ 12.4 B australiaAustralia
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 6.51 -2.54 % $ 64.4 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 22.92 0.17 % $ 1.07 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 105.19 2.21 % $ 27.2 B germanyGermany
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.0 -1.32 % $ 4.94 M israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.43 1.78 % $ 368 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.24 -1.85 % $ 453 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.47 -0.24 % $ 3.11 B usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.99 0.6 % $ 804 M britainBritain
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.58 -1.25 % $ 420 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.2 4.35 % $ 14.6 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 3.31 -3.92 % $ 333 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
$ 6.73 -0.88 % $ 192 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
- -0.88 % $ 598 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA